Anteris Technologies Global Corp. Price & Performance (AVR)

Anteris Technologies has announced significant progress in its DurAVR® Transcatheter Heart Valve (THV) system. The company is set to submit an Investigational Device Exemption (IDE) to the FDA in Q1 2025, aiming to initiate a pivotal trial. This marks a critical step in its mission to address severe aortic stenosis.123

Anteris Technologies' stock dropped by 6.2%, closing at $6.83. This follows a period of strategic reorganization, including an IPO and product development for its DurAVR® THV. Analysts remain optimistic, with price targets reaching up to $22, highlighting potential growth despite current market pressures.45

Anteris Technologies reported a $76 million net loss for 2024, driven by R&D and operational costs linked to its DurAVR® THV development. Despite these losses, the company raised $88.8 million through a Nasdaq IPO and ended the year with $70.5 million in cash, ensuring resources for its growth initiatives.123